Preventive and therapeutic administration of an indigenous Lactobacillus sp. strain against Proteus mirabilis ascending urinary tract infection in a mouse model.
Probiotics are increasingly being considered as non-pharmaceutical and safe potential alternatives for the treatment and prevention of a variety of pathologies including urinary tract infections. These are the most common infections in medical practice and are frequently treated with antibiotics, which have generated an intense selective pressure over bacterial populations. Proteus mirabilis is a common cause of urinary tract infections in catheterised patients and people with abnormalities of the urinary tract. In this work we isolated, identified and characterised an indigenous Lactobacillus murinus strain (LbO2) from the vaginal tract of a female mouse. In vitro characterisation of LbO2 included acid and bile salts tolerance, growth in urine, adherence to uroepithelial cells and in vitro antimicrobial activity. The selected strain showed interesting properties, suitable for its use as a probiotic. The ability of LbO2 to prevent and even treat ascending P. mirabilis urinary tract infection was assessed using an experimental model in the mouse. Kidney and bladder P. mirabilis counts were significantly lower in mice preventively treated with the probiotic than in non-treated mice. When LbO2 was used for therapeutic treatment, bladder counts of treated mice were significantly lower although no significant differences were detected in P. mirabilis kidney colonisation of treated and non-treated animals. These results are encouraging and prompt further research related to probiotic strains and the basis of their effects for their use in human and animal health.
Fraga
Martín
M
Laboratorio de Microbiología, Instituto de Investigaciones Biológicas Clemente Estable, Avda. Italia 3318, CP 11600, Montevideo, Uruguay.
Scavone
Paola
P
Zunino
Pablo
P
D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use; D001647:Bile Acids and Salts / Q000737:chemistry; D002448:Cell Adhesion; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007668:Kidney / Q000382:microbiology; D007778:Lactobacillus / Q000235:genetics / Q000378:metabolism / Q000472:pathogenicity*; D051379:Mice; D008969:Molecular Sequence Data; D019936:Probiotics / Q000627:therapeutic use*; D011512:Proteus Infections / Q000517:prevention & control / Q000628:therapy*; D011513:Proteus mirabilis / Q000378:metabolism*; D012336:RNA, Ribosomal, 16S / Q000032:analysis; D014552:Urinary Tract Infections / Q000382:microbiology / Q000517:prevention & control / Q000628:therapy*; D014556:Urine / Q000382:microbiology; D019459:Urothelium / Q000166:cytology / Q000382:microbiology
D000890:Anti-Infective Agents; D001647:Bile Acids and Salts; D012336:RNA, Ribosomal, 16S